Your browser doesn't support javascript.
loading
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi, Kazuo; Toyoda, Masao; Kimura, Moritsugu; Hatori, Nobuo; Furuki, Takayuki; Sakai, Hiroyuki; Takihata, Masahiro; Umezono, Tomoya; Ito, Shun; Suzuki, Daisuke; Takeda, Hiroshi; Kanamori, Akira; Degawa, Hisakazu; Yamamoto, Hareaki; Machimura, Hideo; Mokubo, Atsuko; Chin, Keiichi; Obana, Mitsuo; Hishiki, Toshimasa; Aoyama, Kouta; Nakajima, Shinichi; Umezawa, Shinichi; Shimura, Hidetoshi; Aoyama, Togo; Sato, Kazuyoshi; Miyakawa, Masaaki.
Afiliação
  • Kobayashi K; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Toyoda M; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Kimura M; 2 Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
  • Hatori N; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Furuki T; 2 Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
  • Sakai H; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Takihata M; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Umezono T; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Ito S; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Suzuki D; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Takeda H; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Kanamori A; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Degawa H; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Yamamoto H; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Machimura H; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Mokubo A; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Chin K; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Obana M; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Hishiki T; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Aoyama K; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Nakajima S; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Umezawa S; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Shimura H; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Aoyama T; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Sato K; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Miyakawa M; 1 Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
Diab Vasc Dis Res ; 16(1): 103-107, 2019 01.
Article em En | MEDLINE | ID: mdl-30284913
ABSTRACT

AIM:

The aim of this study was to assess the renal effects of the glucose-lowering SGLT2 inhibitors in Japanese type 2 diabetes mellitus patients with chronic kidney disease.

METHODS:

The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. Clinical data of type 2 diabetes mellitus patients with chronic kidney disease, who were prescribed SGLT2 inhibitors in addition to other treatments, were collected and analysed.

RESULTS:

SGLT2i was associated with a fall in HbA1c from 64.1 ± 16.7 mmol/mol (8.0 ± 1.5%) to 56.5 ± 12.9 mmol/mol (7.3 ± 1.2%) ( p < 0.01) in 869 analysed cases, a decrease in urine albumin-creatinine ratio from a median of 47.1 to 41.1 mg/gCr, and decrease in estimated glomerular filtration rate from 77.7 ± 23.9 to 75.0 ± 23.9 mL/min/1.73 m2 ( p < 0.01). The effect on albumin-creatinine ratio was independent of age or stage of estimated glomerular filtration; however, there was a significant negative correlation between albumin-creatinine ratio at the initiation of SGLT2 inhibitor and change in ACR. Multiple linear regression analysis identified use of empagliflozin, ß-blockers, and sulphonylureas, Δsystolic blood pressure at office, serum Cr and albumin-creatinine ratio value at initiation of SGLT2 inhibitor as independent and significant determinants of change in ACR.

CONCLUSIONS:

This study confirmed that the beneficial renal effects of SGLT2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease, similar to those reported in large-scale clinical trials conducted in Western countries.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Insuficiência Renal Crônica / Inibidores do Transportador 2 de Sódio-Glicose / Rim País/Região como assunto: Asia Idioma: En Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Insuficiência Renal Crônica / Inibidores do Transportador 2 de Sódio-Glicose / Rim País/Região como assunto: Asia Idioma: En Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão